<DOC>
	<DOCNO>NCT02893371</DOCNO>
	<brief_summary>The objective retrospective observational study compare commonly prescribe bipolar disorder medication impact : ( 1 ) all-cause mortality ; ( 2 ) hospitalization ; ( 3 ) mood episode ; ( 4 ) suicide attempt self-harm ; ( 5 ) risk drug-induced adverse effect kidney disease/failure metabolic syndrome . In addition , investigator examine heterogeneity treatment effect co-morbidity within pediatric , adult , elderly sub-populations .</brief_summary>
	<brief_title>Longitudinal Comparative Effectiveness Bipolar Disorder Therapies</brief_title>
	<detailed_description>Funded PCORI , objective retrospective observational study perform several safety effectiveness comparison commonly prescribe bipolar disorder medication . The study retrospective cohort study conduct administrative claim data Truven MarketScan Commerical Claims Encounters Medicare database 2010-2016 . The database contain approximately 100 million patient within US population every state nearly every county nation , across age , ethnicity socioeconomic category , include privately insure , Medicare patient . The study focus approximately 1 million patient two diagnosis bipolar disorder claim record accord ICD-9 and/or ICD-10 coding . The treatment compare : mood-stabilizers ( 1 ) lithium carbonate ( Lithobid ) ; anticonvulsant ( 2 ) lamotrigine ( Lamictal ) , ( 3 ) valproate ( Depakote ) , ( 4 ) oxcarbazepine ( Trileptal ) , ( 5 ) carbamazepine ( Equetro ) ; atypical antipsychotic ( 5 ) ziprasidone ( Geodon ) , ( 6 ) risperidone ( Risperdal ) , ( 7 ) quetiapine ( Seroquel ) , ( 8 ) olanzapine ( Zyprexa ) , ( 9 ) aripiprazole ( Abilify ) ( 10 ) combination olanzapine/fluoxetine ( Symbyax ) . The investigator perform cross-sectional survival base analysis use regression , propensity scoring , local control perform bias-corrected comparison treatment impact : ( 1 ) all-cause mortality ; ( 2 ) risk hospitalization ; ( 3 ) frequency manic depressive mood episode ; ( 4 ) risk suicide attempt self-harm ; ( 5 ) risk drug-induced adverse effect kidney disease/failure metabolic syndrome . In addition , investigator examine heterogeneity treatment effect co-morbidity within pediatric , adult , elderly sub-populations .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Two instance bipolar disorder diagnosis within administrative claim record Patients less 1 year history database</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>